New article on experimental allergen-specific immunotherapy published in Allergy

Simon Blank and Dennis Russkamp

 

Allergen-specific immunotherapy (AIT) is the only causal treatment for allergy. However, success rates vary depending on the type of allergy and disease background of the patient. Hence, strategies targeting an increased therapeutic efficacy are urgently needed. The research group of Simon Blank in collaboration with the German Mouse Clinic at the Helmholtz Center Munich (first authors: Dennis Russkamp and Antonio Aguilar-Pimentel) used an recombinantly produced IL-4 and IL-13 antagonist (IL-4 Mutein) to block IL-4 and Il-13 signaling during experimental AIT of murine allergic asthma. Using this strategy, they were able to demonstrate that IL-4 and IL-13 blockade during AIT shows beneficial effects on immunological key parameters such as IgE, IgG and Th2 cytokine secretion as well as significantly decreases the number of potentially disease-triggering Th2-biased Tregs (ST2+FOXP3+GATA3intermediate). Hence, Th2 cytokine-inhibiting strategies might be suitable to support allergen-specific immunotherapy in a therapy success-favoring manner.

 

IL-4 receptor α blockade prevents sensitization and alters acute and long-lasting effects of allergen-specific immunotherapy of murine allergic asthma

D. Russkamp, A. Aguilar-Pimentel, F. Alessandrini, V. Gailus-Durner, H. Fuchs, C. Ohnmacht, A. Chaker, M. Hrabe de Angelis, M. Ollert, C. B. Schmidt-Weber, S. Blank

Allergy 2019, Epub ahead pf print.

www.ncbi.nlm.nih.gov/pubmed/30829405

 

We use cookies to improve your experience on our Website. We need cookies to continuously improve the services, to enable certain features and when embedding services or content of third parties, such as video player. By using our website, you agree to the use of cookies. We use different types of cookies. You can personalize your cookie settings here:

Show detail settings
Please find more information in our privacy statement.

There you may also change your settings later.